EUA Requirements — Apply emergency use authorizations to dispensing and documentation requirements - Mpje

SECTION 1

Historical Context & Motivation

The concept of an Emergency Use Authorization (EUA) arises from a fundamental tension in pharmaceutical regulation: the rigorous, multi-year approval process that protects public safety under normal circumstances can become a dangerous bottleneck when a novel pathogen, chemical threat, or radiological emergency demands immediate access to medical countermeasures. Congress recognized this tension following the anthrax attacks of 2001, when the need for rapid deployment of unapproved or investigational products became starkly apparent. The legislative response embedded EUA authority within the broader framework of Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), granting the FDA Commissioner the power to authorize unapproved medical products—or unapproved uses of approved products—when specific statutory criteria are met. For pharmacists, the EUA framework transforms everyday dispensing practice by introducing novel fact sheet requirements, modified informed consent obligations, and unique documentation and adverse event reporting mandates that differ substantially from the standard prescription dispensing workflow.

2001 • Anthrax Attacks Expose Gaps

Following the deliberate mailing of anthrax spores, the federal government recognized the urgent need for mechanisms to distribute unapproved countermeasures rapidly. Existing regulatory pathways proved too slow for crisis-level deployment.

2004 • Project BioShield Act Enacted

Congress passed the Project BioShield Act (P.L. 108-276), which created EUA authority under Section 564 of the FD&C Act, empowering the FDA to authorize unapproved medical products during declared emergencies involving chemical, biological, radiological, or nuclear (CBRN) threats.

2013 • PAHPRA Broadens EUA Scope

The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) expanded EUA authority to cover threats beyond CBRN agents, including naturally emerging infectious diseases, and streamlined the declaration process.

2020–2023 • COVID-19 Pandemic & Unprecedented EUA Use

The SARS-CoV-2 pandemic triggered the most extensive use of EUAs in history. Vaccines, therapeutics (remdesivir, monoclonal antibodies, Paxlovid), and diagnostic tests were authorized under EUA, placing pharmacists at the forefront of dispensing products with unique regulatory requirements.

2024–Present • Post-Pandemic EUA Landscape

Many COVID-era EUAs transitioned to full FDA approval or were revoked. Regulatory agencies and pharmacy boards refined guidance on EUA documentation retention and pharmacist training requirements based on lessons learned.

This historical arc raises a critical question for pharmacy practice: when the standard FDA approval pathway is bypassed in the interest of public health urgency, what specific obligations fall on the pharmacist to ensure that patients receive adequate information, that dispensing conditions are met, and that adverse events are properly tracked? The answer lies in the detailed requirements of each individual EUA and the overarching statutory framework of Section 564.

SECTION 2

Core Principles & Definitions

Before examining the specific dispensing and documentation requirements that EUAs impose, it is essential to understand the foundational principles that distinguish EUA products from traditionally approved drugs, biologics, and devices. An EUA does not constitute FDA approval; rather, it is a time-limited authorization based on a determination that the known and potential benefits outweigh the known and potential risks of the product, given the totality of available scientific evidence. This lower evidentiary threshold carries corresponding obligations to inform patients of the product's investigational status and to collect safety data that would ordinarily emerge during clinical trials.

Emergency Declaration Prerequisite

Before the FDA can issue an EUA, the Secretary of HHS must declare that circumstances exist justifying authorization—typically a determination that a public health emergency exists or a significant potential for one. This declaration is a necessary legal predicate.

Conditions of Authorization

Each EUA specifies binding conditions that must be met by manufacturers, distributors, healthcare providers, and pharmacists. These conditions are tailored to the specific product and may include distribution restrictions, required fact sheets, and adverse event reporting procedures.

Fact Sheet Requirements

Two separate fact sheets are mandated: one for healthcare providers and one for recipients/caregivers. The patient-facing fact sheet must be provided before or at the time of administration, serving as the functional equivalent of informed consent.

Informed Consent & Right to Refuse

Under 21 U.S.C. § 360bbb-3(e)(1)(A)(ii), individuals must be informed of the option to accept or refuse the EUA product and of the consequences, if any, of refusal. This right to refuse is a statutory mandate, not merely a best-practice recommendation.

Adverse Event Reporting

Each EUA outlines specific adverse event reporting requirements, typically through VAERS for vaccines or MedWatch for drugs and devices. Pharmacists must know which system applies and the mandated reporting timeframes for serious adverse events.

✦

KEY TAKEAWAY

Think of an EUA as a conditional driver's permit for a medical product. Just as a learner's permit lets someone drive under specific restrictions—daylight hours, a licensed driver in the passenger seat, certain roads only—an EUA lets a product enter the market under strict conditions. The pharmacist functions like the supervising licensed driver: responsible for ensuring every condition is followed, explaining the rules to the permit holder (patient), and reporting any incidents. If those conditions are violated, the authorization can be revoked.

SECTION 3

Visual Explanation — EUA Authorization & Dispensing Workflow

This diagram illustrates the complete flow from HHS emergency declaration through FDA issuance of an EUA, product distribution to the pharmacy, and the six-step pharmacist dispensing workflow. Note that Step 6 (adverse event reporting) creates a feedback loop to the FDA for ongoing safety surveillance.

The visual above captures the two-phase structure of the EUA system as it applies to pharmacy practice. The upper row depicts the authorization chain—the sequence of federal actions that must occur before a pharmacy even receives an EUA product. The lower two rows detail the pharmacist's dispensing obligations, which are more expansive than for conventionally approved products. Critically, the pharmacist must verify that each patient falls within the EUA's authorized population before dispensing—a step that goes beyond the usual drug utilization review. The dashed box at the bottom reminds practitioners that EUA conditions are dynamic; the FDA may revise fact sheets, modify authorized populations, or revoke the EUA entirely, requiring pharmacists to monitor updates continuously.

SECTION 4

How EUAs Modify Standard Dispensing Requirements

Understanding how EUA dispensing requirements deviate from standard pharmacy practice requires a systematic comparison across multiple dimensions: the legal basis for dispensing, the information provided to patients, the scope of pharmacist authority, and the documentation trail. Under standard conditions, a pharmacist dispenses an FDA-approved drug pursuant to a valid prescription, provides the FDA-approved labeling (including the package insert and any required Medication Guide), and documents the transaction in the prescription record. Under an EUA, several of these elements change in legally significant ways.

Fact Sheet Obligations

The Fact Sheet for Healthcare Providers replaces the traditional prescribing information and package insert for EUA products. It contains product-specific dosing, contraindications, warnings, storage requirements, and the scope of the authorization. The Fact Sheet for Recipients and Caregivers replaces the patient package insert or Medication Guide. Under Section 564(e)(1)(A)(ii) of the FD&C Act, the recipient fact sheet must disclose: (1) that the product is authorized under an EUA and is not FDA-approved; (2) the significant known and potential benefits and risks; (3) the extent to which those benefits and risks are unknown; (4) available alternatives and their benefits and risks; and (5) the right to accept or refuse the product. Pharmacists must ensure that each patient or caregiver receives this fact sheet prior to or at the time of dispensing or administration—not afterward.

Prescriber Authority & Pharmacist Scope Modifications

Some EUAs expand the categories of providers who may prescribe, dispense, or administer the product. During the COVID-19 pandemic, certain EUAs authorized pharmacists to order and administer vaccines without a patient-specific prescription, a significant departure from the traditional prescription-based dispensing model. Other EUAs may restrict dispensing to specific healthcare settings—hospitals, mass vaccination sites, or pharmacies enrolled in a particular distribution program. Pharmacists must verify that their practice setting falls within the EUA's conditions of authorization before dispensing or administering the product.

Documentation & Recordkeeping

EUA products impose documentation requirements that extend beyond the standard prescription record. Pharmacists must record the product lot number, expiration date, and the specific EUA under which the product was dispensed. For vaccines, additional data points include administration site, dose number in a series, the date the fact sheet was provided, and the patient's eligibility category. Many EUAs require that this information be reported to state or federal immunization information systems (IIS). The pharmacist must also maintain documentation confirming that the fact sheet was provided and, where applicable, that the patient was informed of the right to refuse. These records must be retained in compliance with both the EUA's conditions and applicable state pharmacy board regulations, which may specify retention periods of three to ten years or longer.

⚠

CRITICAL DISTINCTION

An EUA product is not an investigational new drug (IND). While both involve products lacking full FDA approval, IND studies operate under informed consent requirements governed by 21 CFR Part 50, whereas EUA informed consent obligations are governed by Section 564 of the FD&C Act. Conflating the two on the MPJE is a common pitfall—know the statutory distinction.

SECTION 5

Documentation Requirements & Adverse Event Reporting

The documentation obligations associated with EUA products represent one of the most practically significant differences from routine dispensing. These obligations span three domains: dispensing records, patient communication records, and adverse event reports. Each domain has specific legal requirements that pharmacists must understand and follow to remain compliant with both federal law and the conditions of the individual EUA.

The three pillars of EUA documentation—dispensing records, patient communication, and adverse event reports—are legally binding conditions of each authorization. The pharmacist must maintain compliance across all three domains simultaneously. Note the distinction between VAERS (for vaccines) and MedWatch (for drugs and devices) as the reporting channels for adverse events.

Adverse Event Reporting Details

The adverse event reporting obligation under an EUA is not merely encouraged—it is a mandatory condition of authorization. For EUA vaccines, pharmacists must report adverse events through the Vaccine Adverse Event Reporting System (VAERS), co-managed by the FDA and CDC. For EUA drugs and devices, the reporting channel is FDA MedWatch (Form 3500). The distinction between these two systems is a frequent MPJE testing point. Serious adverse events—defined as death, life-threatening events, inpatient hospitalization, persistent or significant disability, congenital anomaly, or other medically important conditions—must be reported within the timeframe specified in the EUA, which typically ranges from 7 to 15 calendar days. Pharmacists should also be aware that some EUAs impose reporting obligations for medication errors (even without an adverse outcome), broadening the scope beyond what is required for fully approved products.

SECTION 6

Worked Example — Dispensing an EUA Antiviral

The following scenario walks through the practical application of EUA dispensing and documentation requirements in a community pharmacy setting. This example mirrors the type of applied scenario that may appear on the MPJE.

Scenario: Dispensing an EUA-Authorized Oral Antiviral for COVID-19

1
Step 1 — Receive and Verify the Prescription

A prescriber sends a prescription for an oral antiviral (e.g., nirmatrelvir/ritonavir) to your community pharmacy. The product is currently authorized under an EUA for treatment of mild-to-moderate COVID-19 in adults and pediatric patients ≥12 years weighing ≥40 kg who are at high risk for progression to severe disease. You must first verify that the patient meets the EUA's authorized population criteria. The patient is a 65-year-old male with confirmed COVID-19 (positive test within 5 days of symptom onset) and a history of hypertension—a qualifying high-risk condition.

Patient meets authorized population criteria ✓
2
Step 2 — Review the Healthcare Provider Fact Sheet

Before dispensing, you consult the Fact Sheet for Healthcare Providers, which is the EUA equivalent of prescribing information. You review drug interactions—critically, nirmatrelvir/ritonavir is a potent CYP3A4 inhibitor, and the fact sheet lists extensive contraindicated and dose-adjusted medications. The patient's medication profile includes amlodipine (requires monitoring but not contraindicated) and no contraindicated medications. You confirm renal function: the patient's eGFR is 55 mL/min, which per the EUA fact sheet requires a dose adjustment to nirmatrelvir 150 mg/ritonavir 100 mg BID × 5 days.

Dose adjusted for renal impairment per EUA Fact Sheet: 150 mg/100 mg BID × 5 days ✓
3
Step 3 — Provide the Patient Fact Sheet & Inform of EUA Status

You provide the Fact Sheet for Recipients and Caregivers to the patient (or caregiver) before dispensing the medication. You explain: (a) this product is authorized under an EUA and is not FDA-approved for this use; (b) the known benefits include reduction in hospitalization and death when started within 5 days of symptoms; (c) known risks include altered taste, diarrhea, and drug interactions; (d) alternatives include other EUA-authorized therapeutics or no treatment; and (e) the patient has the right to refuse this product. The patient acknowledges understanding and accepts the medication.

Fact sheet provided prior to dispensing; patient informed of EUA status and right to refuse ✓
4
Step 4 — Dispense and Document

You dispense the medication and record the following in your pharmacy management system and any required state reporting platform: product name, NDC, lot number (e.g., LOT P04521A), expiration date, quantity dispensed (20 nirmatrelvir tablets + 10 ritonavir tablets), EUA reference, date dispensed, patient identifiers (name, DOB, address), prescriber name and NPI, and your dispensing pharmacist identification. You also document that the patient fact sheet was provided and that the patient was informed of the EUA status and the right to refuse.

Complete dispensing record with lot number, EUA reference, and fact sheet provision documented ✓
5
Step 5 — Monitor for Adverse Events and Report if Required

You counsel the patient to contact the pharmacy or prescriber if they experience serious side effects. Two days later, the patient's caregiver calls reporting that the patient was hospitalized with severe hepatic transaminitis. Because this is a serious adverse event (inpatient hospitalization) associated with an EUA product, you are obligated to report it to FDA MedWatch (not VAERS, because this is a drug, not a vaccine) within the timeframe specified in the EUA conditions—typically within 15 calendar days for drugs. You complete FDA Form 3500 and submit it, documenting the report in the patient's pharmacy record.

Serious adverse event reported to FDA MedWatch within mandated timeframe ✓

SECTION 7

EUA vs. Full Approval vs. IND — Dispensing Comparisons

One of the most testable areas on the MPJE involves distinguishing the dispensing and documentation requirements for products under different regulatory statuses. The table below provides a side-by-side comparison of an FDA-approved product, an EUA product, and an investigational new drug (IND) to highlight the key differences that pharmacists must understand.

Feature	FDA-Approved Product	EUA Product	IND Product
Legal basis	NDA/BLA/ANDA (full review)	Section 564 FD&C Act	21 CFR Part 312 (clinical trial)
Evidentiary standard	Substantial evidence of safety & efficacy	Benefits may outweigh risks based on available evidence	Sufficient safety data to justify human exposure
Patient information	Package insert, Medication Guide (if REMS)	EUA Fact Sheet for Recipients (mandatory)	IRB-approved Informed Consent Form
Right to refuse	Patient autonomy (general principle)	Statutory right—must be explicitly communicated	Right to withdraw per 21 CFR 50.25
Prescription required?	Yes (unless OTC)	Depends on EUA conditions; may not require Rx	No—dispensed per protocol by PI
AE reporting	Voluntary (MedWatch); mandatory for REMS	Mandatory per EUA conditions (VAERS or MedWatch)	Mandatory per IND protocol (sponsor reports to FDA)
Labeling	FDA-approved labeling	EUA Fact Sheets (not FDA-approved labeling)	Investigational labeling per 21 CFR 312.6
Duration	Indefinite (unless withdrawn)	Duration of emergency declaration (revocable)	Duration of clinical trial

Comparison of dispensing and documentation requirements by regulatory status

✦

KEY TAKEAWAY

Think of the regulatory landscape as a spectrum of evidence-based confidence. A fully approved product is like a peer-reviewed, published research paper—vetted through extensive review. An EUA product is like a promising preprint during a crisis—the data look favorable enough to act on, but the full review is still pending, so extra safeguards (fact sheets, mandatory AE reporting, right to refuse disclosure) fill the gap. An IND product is like an experiment still in progress—the tightest controls of all, with IRB oversight and formal consent protocols. Understanding where each category falls on this spectrum helps you predict what additional obligations apply.

SECTION 8

Transition from EUA to Full Approval & State-Level Considerations

A critical concept for MPJE preparation is the transition from EUA to full FDA approval (or licensure, in the case of biologics). When a product receives full approval—such as the transition of certain COVID-19 vaccines from EUA to Biologics License Application (BLA) approval—the dispensing requirements change. The EUA-specific fact sheets are replaced by the FDA-approved prescribing information, the mandatory right-to-refuse disclosure under Section 564 no longer applies (though ethical informed consent obligations remain), and adverse event reporting reverts to the standard voluntary MedWatch framework unless a Risk Evaluation and Mitigation Strategy (REMS) is imposed. However, the transition is not always clean: during the COVID-19 pandemic, both EUA-authorized and fully licensed versions of the same vaccine coexisted in the supply chain, creating confusion about which documentation requirements applied to the specific lot being administered.

Aspect	Under EUA	After Full Approval
Patient information document	EUA Fact Sheet for Recipients (mandatory)	FDA-approved Medication Guide or PPI (if applicable)
Right to refuse disclosure	Statutorily required under § 564	Standard informed consent principles apply
AE reporting	Mandatory per EUA conditions	Voluntary (unless REMS)
Labeling source	EUA Fact Sheets (updated by FDA)	FDA-approved labeling (package insert)
Pharmacist authority to administer	As specified in EUA conditions	As permitted by state law and collaborative practice agreements

Key changes when an EUA product transitions to full FDA approval

State-level considerations add another layer of complexity. While EUAs are federal authorizations, state boards of pharmacy retain authority over pharmacist scope of practice, record retention periods, and dispensing protocols. Some states adopted emergency orders during the COVID-19 pandemic that expanded pharmacist authority beyond what the EUA itself authorized—for example, permitting pharmacists to prescribe Paxlovid under a statewide protocol. Conversely, some states imposed additional documentation requirements beyond those in the federal EUA. MPJE candidates must recognize that when federal EUA conditions and state pharmacy law conflict, the pharmacist must comply with the more restrictive standard. This principle of defaulting to the stricter requirement is a foundational concept in pharmacy jurisprudence that applies across all areas of practice, not just EUAs.

ℹ

FORWARD-LOOKING NOTE

Federal legislation proposed in the post-pandemic period aims to refine EUA authority, including proposals to standardize adverse event reporting timelines, establish clearer transition protocols from EUA to full approval, and mandate pharmacist-specific training modules for EUA product dispensing. Stay current with FDA guidance documents and NABP updates as this regulatory landscape continues to evolve.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient presents at your pharmacy with a prescription for a newly EUA-authorized monoclonal antibody for post-exposure prophylaxis of a novel respiratory pathogen. The patient asks, 'Is this FDA-approved?' How should the pharmacist respond, and what specific information must be communicated before dispensing?

Show answer

The pharmacist must clearly inform the patient that the monoclonal antibody is NOT FDA-approved but is authorized for emergency use under an EUA issued by the FDA. Before dispensing, the pharmacist is legally required under Section 564(e)(1)(A)(ii) of the FD&C Act to provide the Fact Sheet for Recipients and Caregivers, which discloses the EUA status, known and potential benefits, known and potential risks, the extent to which benefits and risks are unknown, available alternatives and their benefits/risks, and the patient's statutory right to accept or refuse the product and the consequences of refusal. Simply answering the patient's question verbally is insufficient—the written fact sheet must be provided prior to or at the time of dispensing.

Question 2: BASIC

A pharmacist administers an EUA-authorized vaccine and subsequently learns that the patient experienced anaphylaxis requiring emergency department treatment 30 minutes after administration. To which reporting system must the pharmacist submit this adverse event report, and within what general timeframe?

Show answer

Because the product is a vaccine, the pharmacist must report the adverse event through the Vaccine Adverse Event Reporting System (VAERS), not MedWatch. VAERS is co-managed by the FDA and CDC and is the designated reporting system for vaccine-related adverse events. The anaphylaxis event constitutes a serious adverse event (life-threatening condition requiring emergency medical intervention), and the EUA's conditions of authorization typically mandate reporting of serious adverse events within 7 calendar days, though pharmacists should verify the specific timeframe in the applicable EUA. This reporting is mandatory, not voluntary—a key distinction from adverse event reporting for fully FDA-approved vaccines, where MedWatch/VAERS reporting is generally voluntary unless a REMS is in place.

Question 3: INTERMEDIATE

Your pharmacy has two lots of the same COVID-19 vaccine in stock. Lot A is labeled under an EUA, and Lot B carries FDA-approved (BLA-licensed) labeling. A patient presents for vaccination. Which lot do you use, and how do the documentation requirements differ depending on your choice?

Show answer

Either lot may be administered, as both are the same formulation and are interchangeable per FDA guidance. However, the documentation requirements differ significantly based on which lot is used. If you administer Lot A (EUA), you must provide the EUA Fact Sheet for Recipients, inform the patient of the EUA status and the right to refuse, document provision of the fact sheet, record the lot number and EUA reference, and comply with mandatory adverse event reporting through VAERS as specified in the EUA conditions. If you administer Lot B (BLA-approved), you follow standard dispensing documentation: provide the Vaccine Information Statement (VIS) as required by the National Childhood Vaccine Injury Act, record lot number and administration details, and adverse event reporting reverts to the standard VAERS framework (which is mandatory for certain listed events under the NCVIA for covered vaccines, but the EUA-specific mandatory reporting conditions no longer apply). The critical takeaway is that the lot number on the vial determines the regulatory framework governing your documentation obligations.

Question 4: APPLIED

A community pharmacy in State X receives EUA-authorized oral antivirals for a novel influenza strain. The EUA conditions authorize dispensing by pharmacists without a patient-specific prescription, but State X pharmacy law requires a prescription for all legend drugs. The state board has not issued any emergency orders. Can the pharmacist dispense the antiviral without a prescription? Explain the legal reasoning.

Show answer

No, the pharmacist cannot dispense without a prescription in this scenario. Although the federal EUA conditions authorize dispensing without a patient-specific prescription, State X pharmacy law requires a prescription for all legend drugs, and the state board has not issued an emergency order modifying this requirement. When federal EUA conditions and state pharmacy law conflict, the pharmacist must comply with the more restrictive standard—a fundamental principle of pharmacy jurisprudence. In this case, state law is more restrictive than the EUA, so the pharmacist must obtain a valid prescription before dispensing the antiviral, even though the EUA would otherwise permit dispensing without one. The pharmacist should communicate this limitation to patients and prescribers, contact the state board for clarification, and advocate for an emergency order if the prescription requirement creates a barrier to timely access during the public health emergency. This scenario illustrates why pharmacists must be familiar with both federal EUA conditions and their state's specific pharmacy practice act.

Question 5: CRITICAL THINKING

Consider this scenario: The FDA revokes an EUA for a therapeutic product on Tuesday. Your pharmacy has remaining stock of the product and several patients with active prescriptions. A patient arrives Wednesday morning to pick up a refill that was prepared Monday (before the revocation). Analyze the pharmacist's legal obligations regarding: (a) dispensing the prepared prescription, (b) managing remaining inventory, (c) patient notification, and (d) documentation.

Show answer

This is a complex scenario requiring analysis across multiple domains. (a) Dispensing: Once an EUA is revoked, the legal authority to dispense the product under that authorization ceases. The pharmacist cannot dispense the prepared prescription, even though it was filled before the revocation, because the EUA no longer provides a lawful basis for the product's distribution—the product reverts to unapproved status. Some EUA revocation orders include transition provisions allowing completion of therapy for patients already receiving the product; the pharmacist must read the specific revocation notice carefully. (b) Inventory: The remaining stock can no longer be dispensed. The pharmacist should quarantine the inventory, contact the manufacturer or distributor for return/disposition instructions, and follow any guidance in the revocation notice. (c) Patient notification: The pharmacist must inform the patient that the EUA has been revoked, the product can no longer be dispensed, and alternative treatment options should be discussed with the prescriber. If the patient was mid-course on therapy, the prescriber should be contacted promptly. (d) Documentation: The pharmacist should document the revocation date, the decision not to dispense, communication with the patient and prescriber, inventory quarantine actions, and any instructions received from the manufacturer or FDA. Records of all EUA-related dispensing that occurred prior to revocation must be retained per state board requirements and the terms of the original EUA, as these records may be needed for post-market safety surveillance or regulatory inquiries. This scenario underscores the dynamic nature of EUAs and the pharmacist's responsibility to monitor FDA communications continuously.

SUMMARY

Lesson Summary

Summary

Emergency Use Authorizations (EUAs) are time-limited FDA authorizations issued under Section 564 of the FD&C Act when the Secretary of HHS declares an emergency justifying their use. Unlike fully FDA-approved products, EUA products carry a lower evidentiary threshold—the known and potential benefits must outweigh the known and potential risks—and impose unique obligations on pharmacists. These include providing the Fact Sheet for Recipients and Caregivers prior to dispensing, explicitly informing patients of the product's EUA (non-approved) status, disclosing their statutory right to accept or refuse the product, and conducting mandatory adverse event reporting through VAERS (vaccines) or MedWatch (drugs/devices).

Documentation for EUA products extends beyond standard prescription records to include lot numbers, EUA reference numbers, fact sheet provision confirmation, and for vaccines, administration details and reporting to immunization information systems (IIS). When EUA products transition to full FDA approval, the EUA-specific fact sheets, mandatory right-to-refuse disclosure, and mandatory AE reporting requirements generally cease—replaced by standard approved-product obligations. Finally, when federal EUA conditions and state pharmacy law conflict, pharmacists must always comply with the more restrictive standard—a principle fundamental to pharmacy jurisprudence across all practice areas.